This article is more than 5 years old. Information may no longer be current.
Cyrex launches Array 3 wheat/gluten reactivity, autoimmunity test panel
Click Here to Manage Email Alerts
Cyrex Laboratories has launched the Array 3 wheat/gluten proteome reactivity and autoimmunity test panel, the “most advanced” of its kind, according to a press release.
Designed to distinguish between celiac and non-celiac gluten sensitivity, the Array 3 is the only wheat/gluten panel that tests for three antigen triggers: gluten proteins, opioid peptides and tissue binding isolates, the release said. Furthermore, it detects gluten reactivity and assesses antibody production against eight wheat proteins and peptides, three essential enzymes (transglutaminase-2, -3 and -6), and the gliadin transglutaminase complex.
“Based on articles published in scientific journals, an astounding 50% of patients diagnosed with celiac disease receive a false negative test result when measuring only deamidated alpha gliadin-33-mer antibody,” Aristo Vojdani, PhD, MSc, chief scientific advisor for Cyrex Laboratories, said in the press release. “This is problematic because these gluten-reactive patients, who do not respond to alpha-gliadin-33-mer, instead may react to one or more of the other gluten proteins that are not being measured by other testing panels. This problem is exactly why Array 3 was developed.”
According to the release, the Array 3 is recommended for patients with non-responsive gastrointestinal symptoms, those who present with multiple-symptom complaints such as joint pain, fatigue, muscle pain, brain fog, hormone imbalances and chronic inflammation, and those with depression or neurodegenerative symptoms.
Disclosure: Vojdani is affiliated with Cyrex Laboratories.